The Split Vote: UroGen and the FDA скачать в хорошем качестве

The Split Vote: UroGen and the FDA

When an FDA panel held her company’s future in the balance, UroGen Pharma CEO Liz Barrett refused to fold, even with the odds stacked, a plunging stock, and one vote deciding it all. PODCAST TEAM Producer and Director: Devon Leaver Editor: Dominique Guerra Production Coordinator: YingYu Lin Production Support: Annabelle Chan Story Consultants: Partner & Research Analyst Tony Nguyen, and Chief Corporate Finance Officer, Chris Seiter. Featuring: Liz Barrett, President & CEO of UroGen Pharma, moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments, LP. FOLLOW US Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website (https://www.rtwfunds.com/podcasts/?ut..., for the latest updates and insights. To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify (https://open.spotify.com/show/09VhEfY..., Apple Podcasts (https://podcasts.apple.com/us/podcast..., Amazon Music (https://music.amazon.de/podcasts/b971..., and most other podcast platforms. CHAPTERS 00:00 - Introduction 00:54 – Liz Barrett’s pharma journey 03:26 - UroGen: the product and the pipeline 08:36 - The FDA vote on UroGen 15:13 - UroGen and RTW’s relationship 18:48 - Liz Barrett’s leadership style 22:47 - Outro DISCLAIMER This interview was given by Liz Barrett, President & CEO of UroGen Pharma, and moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments, LP. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.